In addition, treating mice or human MM patient samples with anti-CD84 blocking antibody reduces the amount of MDSCs and their immunosuppression, leading to an increase in the antitumor response of T cells; this results in a reduction in the amount of tumor cells in a dose-dependent manner and increased mouse survival. This evidence concerns the gene CD84 and neoplasm.